+91 8617752708

Journal of Advances in Biology & Biotechnology, 2394-1081,Vol.: 14, Issue.: 2

Review Article

Technological and Patent Evolution of Murine Monoclonal Antibodies

 

Kátia dos Reis1*, José Procópio Moreno Senna1, Nei Pereira Júnior2 and Maria Antonieta Peixoto Gimenes Couto2

1Institute of Technology in Immunobiology Biomanguinhos (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz), Av. Brasil, 4365 –Manguinhos, 21040-900, Rio de Janeiro, RJ, Brasil.

2Department of Engineering Biochemistry, Federal University of Rio de Janeiro (UFRJ), Av. Horácio Macedo, 2030, Centro de Tecnologia, Bloco E, sala E-203, Cidade Universitária 21941-909, Rio de Janeiro, RJ, Brasil.

Article Information

Editor(s):

(1) Laura Pastorino, Laboratory of Nanobioscience and Medical Informatic, Department Informatics, Bioengineering, Robotics and Systems Engineering (DIBRIS), University of Genoa, Italy.

Reviewers:

(1) Denong Wang, USA.

(2) Toshi Nagata, Hamamatsu University School of Medicine, Japan.

(3) Mahana, University Paris-Saclay, France.

Complete Peer review History: http://www.sciencedomain.org/review-history/20290

Abstracts

Among the pharmaceutical products targeted for patent protection, monoclonal antibodies stand out. Technological advances involving monoclonal antibodies aim to minimize detrimental human immune responses to antibodies (e.g., human anti-murine antibodies [HAMA]) and increase the binding affinity of antibodies to their antigen, making them more specific for their therapeutic target. This work evaluates the main technological advances pertaining to monoclonal antibodies, from the creation of technology for the immortalization of cells to generate hybridomas through the generation of chimeric and humanized antibodies by genetic engineering techniques, phage display technology, and transgenic mice. It also aims to provide an overview of commercially available and patented murine monoclonal antibodies and to correlate the main players, markets, and therapeutic uses for which the antibodies were developed. The study of mMAB (murine monoclonal antibodies) proved to be of great importance to understand how the development of these antibodies and their protection by patents affects their therapeutic use in cancer patients, in diagnostics, to treat inflammation, etc. The United States (US), Japan (JP), France (FR), and China (CN) constitute potential markets for these protected technological advances. Among current usage trends of three murine monoclonal antibodies whose patents have expired, the use of generic and/or biosimilar is evidenced, as well as the use of these assets to guarantee the protection of new products, new associated processes (e.g., new combinations, associations, or dosage forms), or new processes. The newest market trends related to patent protection in this technological area incorporate the use of monoclonal antibody fragments.

Keywords :

Murine monoclonal antibodies; patents; Biopharmaceuticals; Intellectual property.

Full Article - PDF    Page 1-11

DOI : 10.9734/JABB/2017/34759

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,
India

+91 8617752708

 

Third Floor, 207 Regent Street
London, W1B 3HH,
UK

+44 20-3031-1429